Published Medical Literature

CALGB 90601: Combination Gemcitabine and Cisplatin With Bevacizumab in Urothelial Carcinoma

Resistant Urothelial Carcinoma: Organ-Specific Response to Pembrolizumab

The Hormone Ghrelin: Potential Prognostic Predictor in Muscle-Invasive Bladder Cancer?

Rare Complication of Intravesical BCG Therapy for Bladder Cancer: Case Report

Is Dietary Acrylamide Intake Associated With the Development of Bladder Cancer?

Does a Family History of Any Cancer Increase the Risk for Bladder Cancer?

Do Men and Women With Urinary Bladder Cancer Respond Differently to BCG Immunotherapy?

Can Treatment-Specific COXEN Scores Predict Responses to Neoadjuvant Chemotherapy for Bladder Cancer?

Diagnostic Utility of Serum N‐glycan Profiles in Urothelial Carcinomas

TP53-Mutated Bladder Cancer: Identifying Patients Who May Benefit From Immunotherapy

Does Use of Aspirin Improve Outcomes in Older Adults With Bladder Cancer?

Prescription of Psychotropic Drugs in Older Patients With Bladder Cancer

Low-Dose BCG Tokyo Strain for Non–Muscle-Invasive Bladder Cancer

Unleashing the Therapeutic Potential of Natural Compounds Against Bladder Cancer

Systemic Treatment of Metastatic Bladder Cancer: Dutch Study of Current Clinical Practice

Radical Cystectomy Versus BCG Treatment for High-Risk Bladder Cancer

Novel Prognostic Biomarker for Bladder Cancer Investigated

Immunotherapy for Urothelial Cancer: Balancing Benefits and Risks

Preferred Treatment for Invasive Bladder Cancer: Intravesical Immunotherapy or Radical Cystectomy?

Measures of Tumor Heterogeneity: Useful Biomarkers of Bladder Carcinoma?

Study Identifies Potential Biomarker of Bladder Carcinoma Recurrence

Impact of Preoperative Positive Voided Urine Cytology on Prognosis in Urothelial Cancer

Intravesical Nadofaragene Firadenovec in Non–Muscle Invasive Bladder Cancer

Ramucirumab Plus Docetaxel in Urothelial Carcinoma: Patient-Reported Outcomes From RANGE Trial

Pelvic Radiotherapy Combined With Chemotherapy in Metastatic Urothelial Cancer

Predicting Risk of Recurrence in Nonmuscle‐Invasive Bladder Cancer

Preoperative Chemotherapy for High-Grade Upper Tract Urothelial Carcinoma

Nab-paclitaxel Versus Paclitaxel in Metastatic Urothelial Cancer

Surveillance Strategy for Patients With Upper Tract Urothelial Carcinoma

Dose-Dense Chemotherapy for Muscle-Invasive Bladder Cancer: Phase III Trial Toxicity Update

Case Study: Neoadjuvant Pembrolizumab in Chemoresistant Urothelial Carcinoma

Targeting Bladder Carcinoma in Situ With Novel Gene Therapy

After Surgery for Upper Urinary Tract Urothelial Carcinoma: Surveillance or Chemotherapy?

Potential Genomic Predictors of Outcomes in High-Grade T1 Bladder Cancer

DANUBE Trial: Survival Outcomes With Durvalumab in Advanced Urothelial Carcinoma

Combination Regimen Under Study in Metastatic Urothelial Carcinoma

Update on Managing Non–Muscle-Invasive Bladder Cancer

Can Leukocyte Telomere Length Predict Bladder Cancer Risk?

Bladder Urothelial Carcinoma: Is Age Related to Risk of Lymph Node Metastasis?

Early Results With Buparlisib in Treatment of Metastatic Urothelial Carcinoma

Testicular Tuberculosis: Case Study of Rare Complication of Urothelial Cancer Treatment

Perioperative Chemotherapy for High‐Risk Upper Tract Urothelial Carcinoma

Early Findings With Magnetic Resonance–Guided Radiotherapy for Bladder Cancer